Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review

被引:5
|
作者
Gopalan, Sarath [1 ]
Ganapathy, Sridhar [2 ]
Mitra, Monjori [3 ]
Neha [4 ]
Joshi, Devesh Kumar [4 ]
Veligandla, Krishna C. [4 ]
Rathod, Rahul [5 ]
Kotak, Bhavesh P. [4 ]
机构
[1] Madhukar Rainbow Childrens Hosp, Pediat, New Delhi, India
[2] Janani Childrens Hosp, Pediat, Mumbai, India
[3] Inst Child Hlth ICH, Pediat, Kolkata, India
[4] Dr Reddys Labs Ltd, Med Affairs, Hyderabad, India
[5] Dr Reddys Labs Ltd, Ideat & Clin Res Med Affairs, Hyderabad, India
关键词
cncm i-745; paediatric acute gastroenteritis; antibiotic-associated diarrhoea; saccharomyces boulardii; probiotic; ANTIBIOTIC-ASSOCIATED DIARRHEA; ACUTE GASTROENTERITIS; PREVENTION; EFFICACY; SAFETY; METAANALYSIS; CHILDREN;
D O I
10.7759/cureus.46314
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Probiotics, both bacterial and yeast, have long been associated with a beneficial health history and human well-being. Among yeasts, Saccharomyces is a genus that is efficacious in rendering better human health, with Saccharomyces boulardii (S. boulardii) CNCM I-745 being classified as a probiotic agent. The present review highlights the unique properties of S. boulardii and its role in the prevention of antibiotic-associated diarrhea (AAD) and pediatric acute gastroenteritis (PAGE) in comparison to bacterial probiotics. Its unique properties, such as viability over a wide pH range, inability to acquire antibiotic resistance genes, and property to achieve a steady state rapidly, have given S. boulardii an edge over bacterial probiotics. In AAD patients, prophylactic use of S. boulardii has shown a significantly lower risk of AAD (in comparison to controls) and restored the diversity of gut microbiota. Among Indian children with PAGE, S. boulardii CNCM I-745 was found superior to Lactobacillus rhamnosus GG and four strains of Bacillus clausii in shortening the duration of diarrhea and reducing the length of hospital stay. S. boulardii CNCM I-745 being considered a safe probiotic for use in children and adults also finds recommendations in several international guidelines for the management of acute diarrhea. The current review discusses evidence for the proven efficacy and safety of S. boulardii CNCM I-745 as a probiotic for preventing gastrointestinal disorders.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Effects of Probiotic Fermented Fruit Juice- Based Biotransformation by Lactic Acid Bacteria and Saccharomyces boulardii CNCM I-745 on Anti-Salmonella and Antioxidative Properties
    Laosee, Wanida
    Kantachote, Duangporn
    Chansuwan, Worrapanit
    Sirinupong, Nualpun
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2022, 32 (10) : 1315 - 1324
  • [22] The Saccharomyces boulardii CNCM I-745 Strain Shows Protective Effects against the B. anthracis LT Toxin
    Pontier-Bres, Rodolphe
    Rampal, Patrick
    Peyron, Jean-Francois
    Munro, Patrick
    Lemichez, Emmanuel
    Czerucka, Dorota
    TOXINS, 2015, 7 (11): : 4455 - 4467
  • [23] Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral diarrhoea in adults: results from a single-centre randomized trial
    Salazar-Parra, Marcela A. G.
    Cruz-Neri, Roberto U.
    Trujillo-Trujillo, Xochitl A. R.
    Dominguez-Mora, Juan J.
    Cruz-Neri, Hector, I
    Guzman-Diaz, Jazmin M.
    Guzman-Ruvalcaba, Mario J.
    Vega-Gastelum, Jesus O.
    Ascencio-Diaz, Kriscia, V
    Zarate-Casas, Maria F.
    Gonzalez-Ponce, Fanny Y.
    Barbosa-Camacho, Francisco J.
    Fuentes-Orozco, Clotilde
    Cervantes-Guevara, Gabino
    Cervantes-Perez, Enrique
    Cervantes-Cardona, Guillermo Alonso
    Cortes-Flores, Ana Olivia
    Gonzalez-Ojeda, Alejandro
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [24] Effectiveness of Saccharomyces boulardii CNCM I-745 in Adult Indian Patients with Diarrhoea: A Real-world, Multicentre, Retrospective, Comparative Study
    Pal, Bhaskar Bikash
    Bandagi, Rupali Vinodchandra
    Pebbili, Kranthi Kiran
    Rathod, Rahul
    Kotak, Bhavesh
    Dhanaki, Gauri
    Shah, Snehal
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (02) : 309 - 316
  • [25] A double-blinded randomized trial on growth and feeding tolerance with Saccharomyces boulardii CNCM I-745 in formula-fed preterm infants
    Xu, Lingfen
    Wang, Yun
    Wang, Yang
    Fu, Jianhua
    Sun, Mei
    Mao, Zhiqin
    Vandenplas, Yvan
    JORNAL DE PEDIATRIA, 2016, 92 (03) : 296 - 301
  • [26] Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis
    Altcheh, Jaime
    Carosella, Mabel V.
    Ceballos, Ana
    D'Andrea, Ulises
    Jofre, Sandra M.
    Marotta, Carolina
    Mugeri, Domingo
    Sabbaj, Liliana
    Soto, Adriana
    Josse, Constant
    Montestruc, Francois
    McFarland, Lynne V.
    MEDICINE, 2022, 101 (36) : E30500
  • [27] Prospective randomized controlled study on the effects of &ITSaccharomyces boulardii&IT CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers
    Kabbani, Toufic A.
    Pallav, Kumar
    Dowd, Scot E.
    Villafuerte-Galvez, Javier
    Vanga, Rohini R.
    Castillo, Natalia E.
    Hansen, Joshua
    Dennis, Melinda
    Leffler, Daniel A.
    Kelly, Ciaran P.
    GUT MICROBES, 2017, 8 (01) : 17 - 32
  • [28] Saccharomyces boulardii Strain CNCM I-745 Modifies the Mononuclear Phagocytes Response in the Small Intestine of Mice Following Salmonella Typhimurium Infection
    Ibanez, Lidia
    Pontier-Bres, Rodolphe
    Larbret, Frederic
    Rekima, Akila
    Verhasselt, Valerie
    Blin-Wakkach, Claudine
    Czerucka, Dorota
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [29] Saccharomyces boulardii (CNCM I-745) ameliorates Ovalbumin-induced atopic dermatitis by modulating the NF-κB signaling in skin and colon
    Buttar, Parveen Akhtar
    Mazhar, Muhammad Usama
    Khan, Jehan Zeb
    Jamil, Maryam
    Abid, Muhammad
    Tipu, Muhammad Khalid
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2025, 317 (01)
  • [30] Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury
    D'Antongiovanni, Vanessa
    Antonioli, Luca
    Benvenuti, Laura
    Pellegrini, Carolina
    Di Salvo, Clelia
    Calvigioni, Marco
    Panattoni, Adelaide
    Ryskalin, Larisa
    Natale, Gianfranco
    Banni, Sebastiano
    Carta, Gianfranca
    Ghelardi, Emilia
    Fornai, Matteo
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 (24) : 3215 - 3233